...
首页> 外文期刊>Diabetes care >Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study.
【24h】

Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study.

机译:在糖尿病预防计划和糖尿病预防计划结果研究期间,抗抑郁药的使用和患糖尿病的风险。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS). RESEARCH DESIGN AND METHODS: DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up. RESULTS: Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32-4.15]) and lifestyle (2.48 [1.45-4.22]) arms, but not in the metformin arm (0.55 [0.25-1.19]). CONCLUSIONS: Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.
机译:目的:在糖尿病预防计划(DPP)和糖尿病预防计划结果研究(DPPOS)中评估抗抑郁药的使用与患糖尿病风险之间的关系。研究设计和方法:对DPP / DPPOS参与者每6个月进行一次糖尿病评估,在DPP中每3个月评估一次抗抑郁药的使用,在DPPOS中每6个月评估抗抑郁药的使用,进行中位10.0年的随访。结果:在控制与糖尿病风险有关的因素后,与不使用抗抑郁药相比,连续服用抗抑郁药与安慰剂(调整后的危险比2.34 [95%CI 1.32-4.15])和生活方式(2.48 [1.45-4.22])患糖尿病风险有关。 ,但不在二甲双胍臂中(0.55 [0.25-1.19])。结论:连续服用抗抑郁药与安慰剂和生活方式组患糖尿病的风险显着相关。测得的混杂因素和介体不能解释这种关联,这可能代表药物作用或反映了抗抑郁药物使用者和非药物使用者之间在本研究中未评估的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号